Search all trials

Find therapies in clinical trials near you – page 2

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 955
countries: 28
conditions: 2 101

3 955 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Crohn's disease

Recruiting

Investigational

Study of RO7790121 (afimkibart) for Treatment and Long-term Management in Adults with Moderate to Severe Crohn's Disease

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Ro7790121

Contact Research Centre

Colitis ulcerative

Recruiting

Investigational

Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Mirikizumab

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study comparing Rilvegostomig plus chemotherapy versus Pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Breast cancer+1

Recruiting

Investigational

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Sargramostim

Contact Research Centre

Crohn's disease

Recruiting

Investigational

Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Morf-057

Contact Research Centre

Crohn's disease

Recruiting

InvestigationalNo placebo

Study on the Long-Term Effects and Safety of Mirikizumab for Patients with Crohn's Disease

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Mirikizumab

Contact Research Centre

Non-small cell lung cancer metastatic

Recruiting

Registered drugNo placebo

Phase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bms-986340

Contact Research Centre

Colitis ulcerative

Recruiting

InvestigationalNo placebo

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Golimumab

Contact Research Centre

Oesophageal adenocarcinoma

Recruiting

Registered drugNo placebo

Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Calcium Folinate

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Registered drug

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Calcium Folinate

Contact Research Centre

Colitis ulcerative+2

Recruiting

InvestigationalNo placebo

Study of ly4395089 and mirikizumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Mirikizumab

Contact Research Centre

Non-small cell lung cancer stage III

Recruiting

Registered drugNo placebo

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Durvalumab

Contact Research Centre

Find therapies in clinical trials near you – page 2

334 trials match your criteria

Crohn's disease

Study of RO7790121 (afimkibart) for Treatment and Long-term Management in Adults with Moderate to Severe Crohn's Disease

Colitis ulcerative

Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis

Non-small cell lung cancer

Study comparing Rilvegostomig plus chemotherapy versus Pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

Breast cancer+1

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Crohn's disease

Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease

Crohn's disease

Study on the Long-Term Effects and Safety of Mirikizumab for Patients with Crohn's Disease

Non-small cell lung cancer metastatic

Phase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)

Colitis ulcerative

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

Oesophageal adenocarcinoma

Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

Pancreatic carcinoma metastatic

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Colitis ulcerative+2

Study of ly4395089 and mirikizumab in adults with moderately to severely active Crohn’s disease

Non-small cell lung cancer stage III

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.